Ambition
Create innovative drugs for unmet medical needs
Pharma-hub with a global impact

THE COMPANY

KINNOV therapeutics

KINNOV was created as a spin off from Greenpharma and Key-Obs, both located in Orléans, 100 km south of Paris France.

Kinnov-Therapeutics founders have worked on deciphering the pharmacological and biochemical mechanisms of addiction for more than 20 years, resulting in the identification of a disruptive strategy to treat addicted people.

KT-110 is the first project based on this new strategy to positively complete a phase 2 trial.

KT-110 proof of concept clinical trial on alcohol addiction has started in nov 2019, results were available in January 2022. They were positive and very high risk level population is likely to be targeted for phase 3 study.

context

of the project

Addictions are cognitive pathologies defined by a dependency to a substance or an activity, with deleterious consequences.

Tobacco (nicotine) and alcohol are the most common addictions, followed by cannabis, opiates and at to a lesser extent, cocaines, amphetamines and synthetic derivatives. People may also be addicted to activities such as gambling, video game…

Addiction is becoming a serious socio-economic problem. The U.S. market for substance abuse treatment and diagnosis reached $3 billion in 2013, in which pharmaceutical treatments had the largest share with $2.8 billion. Management of increasing addiction and abuse to nicotine, alcohol and illicit prescription drugs costs around $700 billion for the Americans every year.

Furthermore, according to WHO, 280 million peoples suffer of alcohol use disorder world wide, causing 3.3 millions of death each year. Very High risk level population is 11.4 million people in Europe and USA (respectively 5.2 and 6.2 millions). Nevertheless, few therapeutic agents are available and efficient on these pathologies of addiction, to date.

The board :

  • Dr Philippe BERNARD

    Kinnov Therapeutics CEO

    20+ years expertise in Med Chem. Founder and Manager of Greenpharma Is author of more than 50 scientific publications and 20 patents.
    Read more

  • Emmanuel de RIVOIRE

    General Manager

    Senior international executive in Pharma industry with 30+ years experience in Europe, Middle East/Africa and Asia. Strong drive, able to manage complex situations. Excellent track record in performances, company transformation and customer culture program. Previous managing experience at Takeda, Nycomed, Roche, GSK, Abbott.
    Read more

  • Dr Fabrice TROVERO

    KT Preclinical R&D manager

    20+ years expertise in CNS pharmacology. Founder of Key-Obs.
    Read more

  • Prof Jean-Pol TASSIN

    KT Scientific advisor

    Research director at INSERM, head of the team « Physiopathology of dependence and relapse » Inserm unit 952/ CNRS UMR7224, Université Pierre et Marie Curie, Paris VI.
    He is also President of scientific advisory board of MILDT. Member of scientific committee of the European Observatory of Drugs and Toxicomanies.
    He is Laureate for the Prize of the European College of Neurospsychopharmacology (September 2009) for his work and new hypothesis of neurobiological mechanisms of addiction.
    Read more

  • Prof Alain PUECH

    KT clinical project director

    Ph. D. in Pharmacology and a Medical Doctor and has held a number of key positions in his over 30 year career in the pharmaceutical industry including :
    • Professor at the CHU Pitié-Salpétrière(1971-1997).
    • Manager of the International development at Sanofi -Synthelabo (1997-2003).
    • Chief Scientific Officer France Sanofi Aventis (2003-2006).
    He is currently working as a Consultant to industry since 2007.
    Read more

  • Prof Bernard PAU

    KT Business development advisor

    Professor in Immunology and Biotechnology at the University of Montpellier (Faculty of Pharmaceutical sciences); has pioneered in France the transfer of innovation by bridging the gap between academic research and industry in the fields of drug discovery, diagnostic tests and biotechnology; former director of the department of Life sciences at CNRS; formerly with Sanofi Pharmaceutical Group; co-founder of two startup companies: Innodia and I2T; co-author of more than 140 scientific publications and patents; inventor of innovative worldwide marketed diagnostic tests.
    Read more

  • Dr Sylvain YON

    KT Business development advisor

    Sylvain Yon, Ph.D. is the Deputy CEO of Theraclion (www.theraclion.com). In this role, he leads both the research & development efforts of the company and the business expansion on the Asian markets. Sylvain Yon is a co-founder of Echosens, where he headed engineering activities until 2008. He then successfully handled the company’s acquisition by a major player in the Chinese health industry, before joining Theraclion. He is also the founder of several companies in the fields of acoustics and the Internet
    Read more

  • Lucas Biela

    Kinnov Therapeutics Clinical Project Manager

    14+ years of experience in clinical research. Previous experience at Parexel, Onxeo, Danone Research, DBV Technologies
    Read more

SCIENTIFIC BOARD :